CureusSep 12, 2026

GLP-1 and GIP/GLP-1 Receptor Drugs for Weight Gain Caused by Antipsychotic Medicines: A Review

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 14, 2026

Abstract

Second-generation antipsychotics can reduce life expectancy by 10 to 20 years due to severe weight gain and cardiometabolic complications.

Advanced incretin-based therapies may counteract weight gain and cardiometabolic issues linked to antipsychotic medications.
Glucagon-like peptide-1 receptor agonists, like semaglutide, could significantly reduce weight and cardiovascular risks in psychiatric patients without affecting mental health.
The dual-receptor agonist tirzepatide might enhance weight loss and improve metabolic function by targeting multiple pathways.
Preliminary data suggest tirzepatide's potential as a comprehensive metabolic stabilizer for individuals with severe mental illness.
There is a need for a shift toward proactive metabolic protection at the start of antipsychotic treatment to address the longevity crisis in severe mental illness.

Simplified

The clinical management of severe mental illness faces a profound longevity crisis, as second-generation antipsychotics, particularly clozapine and olanzapine, trigger severe weight gain and cardiometabolic complications that reduce life expectancy by 10 to 20 years. Traditional lifestyle modifications and metformin frequently fail because they do not address the hypothalamic disruption and altered reward signaling caused by these medications. This narrative review synthesizes evidence on advanced incretin-based therapies as a novel counter-regulatory strategy. Glucagon-like peptide-1 receptor agonists, specifically semaglutide, have established a robust benchmark, demonstrating significant weight reduction and cardiovascular risk mitigation in psychiatric cohorts without compromising mental stability. Furthermore, the dual-receptor agonist tirzepatide represents a major paradigm shift, leveraging dual-receptor synergy to provide superior weight loss, optimize adipose tissue function, and reduce hepatic steatosis. Although large-scale randomized controlled trials for tirzepatide in severe mental illness are still limited, preliminary data underscore its extensive role as a comprehensive metabolic stabilizer. Ultimately, closing the mortality gap in psychiatry requires a transition from reactive rescue models toward early, proactive metabolic protection at the onset of antipsychotic therapy.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

GLP-1 and GIP/GLP-1 Receptor Drugs for Weight Gain Caused by Antipsychotic Medicines: A Review

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief